The test, TruGraf, assesses differentially expressed genes in blood to rule out subclinical kidney transplant rejection in patients with stable renal function.
While industry organizations remain optimistic the bill will pass, others note challenges, including a lack of strong Congressional support and political gridlock.
According to industry groups, some vendors are reporting providers have returned POC testing systems because the economics of using them no longer makes sense.
